Generic Product News (January 2019)

Pharmacy Times, January 2019 Vaccine-Preventable Disease, Volume 85, Issue 1

MARKETED BY: ANI Pharmaceuticals, Inc

COMPARE TO: Brethine

INDICATION: ANI Pharmaceuticals launched terbutaline sulfate tablets, the generic equivalent to Brethine, for the prevention and treatment of bronchospasms in asthmatic patients over 12 years who have reversible bronchospasms associated with bronchitis and emphysema. The tablets will be available in 2.5- mg and 5.0-mg doses.

DOSAGE FORM: Tablet

FOR MORE INFORMATION: anipharmaceuticals.com

TESTOSTERONE TOPICAL GEL 1.62%

MARKETED BY: Perrigo Company plc

COMPARE TO: AndroGel topical gelINDICATION: The FDA has approved testosterone topical gel as an AB-rated generic equivalent to AndroGel topical gel. The gel works as a replacement therapy for men with a condition that results in the absence or significant reduction of endogenous testosterone. The gel comes in the following doses: 20.25-mg testosterone/1.25-g packet, 40.5-mg testosterone/2.5-g packet, and 20.25-mg/1.25-g actuation pump.

DOSAGE FORM: Gel

FOR MORE INFORMATION: perrigo.com

ROFLUMILAST TABLETS

MARKETED BY: Breckenridge Pharmaceutical, Inc

COMPARE TO: Daliresp

INDICATION: The FDA has approved roflumilast tablets for the prevention of chronic obstructive pulmonary disease (COPD) exacerbation oSrhafplae re-ups in patients with severe COPD associated with chronic bronchitis and past exacerbations. The newly approved ANI;721 drug is generically equivalent to AstraZeneca’sDaliresp.

DOSAGE FORM: Tablet

FOR MORE INFORMATION: bpirx.com

SOFOSBUVIR 400 MG/VELPATASVIR 100 MG AND LEDIPASVIR 90 MG/SOFOSBUVIR 400 MG

MARKETED BY: Gilead Sciences, Inc

COMPARE TO: Epclusa and Harvoni

INDICATION: Gilead Sciences, announced its plans to launch generic versions of its costly treatments for hepatitis C virus. Sofosbuvir 400 mg/ velpatasvir 100 mg will be generically equivalent to Epclusa, and ledipasvir 90 mg/sofosbuvir 400 mg will be generically equivalent to Harvoni. The drugs are expected to be available by January 2019 at a list price of $24,000, allowing patients to save up to $2500 in out-of-pocket costs per therapy course. The generic launch will expand access to lifesaving drugs.

DOSAGE FORM: Tablet

FOR MORE INFORMATION: gilead.com